179 related articles for article (PubMed ID: 20092424)
1. Farletuzumab in epithelial ovarian carcinoma.
Spannuth WA; Sood AK; Coleman RL
Expert Opin Biol Ther; 2010 Mar; 10(3):431-7. PubMed ID: 20092424
[TBL] [Abstract][Full Text] [Related]
2. Role of farletuzumab in epithelial ovarian carcinoma.
Jelovac D; Armstrong DK
Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
[TBL] [Abstract][Full Text] [Related]
3. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
[TBL] [Abstract][Full Text] [Related]
4. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and its use in epithelial ovarian cancer.
Matulonis UA
Future Oncol; 2011 Mar; 7(3):365-79. PubMed ID: 21323425
[TBL] [Abstract][Full Text] [Related]
10. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
13. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
Kristjansdottir K; Dizon D
Expert Opin Biol Ther; 2010 Feb; 10(2):243-50. PubMed ID: 20001562
[TBL] [Abstract][Full Text] [Related]
14. Profile of farletuzumab and its potential in the treatment of solid tumors.
Sato S; Itamochi H
Onco Targets Ther; 2016; 9():1181-8. PubMed ID: 27022278
[TBL] [Abstract][Full Text] [Related]
15. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
Smith-Jones PM; Pandit-Taskar N; Cao W; O'Donoghue J; Philips MD; Carrasquillo J; Konner JA; Old LJ; Larson SM
Nucl Med Biol; 2008 Apr; 35(3):343-51. PubMed ID: 18355690
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Vergote I; Armstrong D; Scambia G; Teneriello M; Sehouli J; Schweizer C; Weil SC; Bamias A; Fujiwara K; Ochiai K; Poole C; Gorbunova V; Wang W; O'Shannessy D; Herzog TJ
J Clin Oncol; 2016 Jul; 34(19):2271-8. PubMed ID: 27001568
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab for the treatment of ovarian cancer.
Langdon SP; Faratian D; Nagumo Y; Mullen P; Harrison DJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1113-20. PubMed ID: 20465533
[TBL] [Abstract][Full Text] [Related]
18. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
[TBL] [Abstract][Full Text] [Related]
19. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
